Skip to main content
Equibles
MLTX logo

MLTX · MoonLake Immunotherapeutics

Track MLTX — free

Use MLTX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MLTX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$11.55 +0.14 (+1.23%)
Rebalance outlook locked
Market Cap
$1.02B
Shares
85.11M
Volume · Oct 5 1.3M Avg daily vol (3M) 1.39M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$11.41 Open$11.64 Day$11.03–11.65 52W close$7.46–22.16 Avg vol 30d1.6M Short int8.9M · 10.5% float · 6.1d Short vol28% Last earningsFeb 23, 2026 DataOct 2020–Oct 2026 Filing10-Q · Aug 10

Up next

Latest filing: 10-Q
filed Aug 10, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$263.05M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-22.0%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+16.8%
Year over year · more shares
Price change (1Y)
+52.9%
Trailing year
Short interest
10.5%
Latest settlement · 6.1 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Neutral Momentum Very Weak Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 15.3 · calm Equity put/call 0.58
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −32%
below
Price vs 50-day avg −25%
below
RSI (14) 29
oversold
MACD trend Positive
52-week position 27%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −25%
trailing
6-month return −38%
trailing
YTD return −13%
this year
Relative strength −50%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $15 › 200d $17 — 200d above 50d
Institutional flow Accumulating
+17% holders QoQ · +44 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
10.51% of float · ▲ +25.2% MoM · 6.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
175 holders — near 3-yr high, broad support
Squeeze score 57
elevated · 0–100
Fundamentals
Weak
EPS growth −87%
Y/Y
Free cash flow $-196.0M
Balance sheet $260.4M
net cash
Quant / Vol
risk profile
Very High
Volatility 74%
annualized · 1-yr
Max drawdown −49%
past year
ATR 5.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
2 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−32% Bearish
Price vs 50-day avg
−25% Bearish
RSI (14)
29 Neutral
MACD trend
Positive Bullish
52-week position
27% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $15 › 200d $17 — 200d above 50d
Institutional flow Accumulating
+17% holders QoQ · +44 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
10.51% of float · ▲ +25.2% MoM · 6.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
175 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $7 Now $11 · 27% Range high $22
vs 200-day avg -32% vs 50-day avg -25%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
MLTX
MoonLake Immunotherapeutics
this stock
$1.02B -13.4% — — 10.5%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $133.37B +11.3% +46.2% 30.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.13B -4.8% +20.8% 19.5 2.5%
MRNA
Moderna, Inc.
 $79.40B +544.3% +4.3% — 8.2%
CSLLY
Csl Ltd
 $61.25B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
175
% held
88.4%
Net QoQ
+10.2M sh
Top holder
BVF INC/IL
Held Float
View
Held by Funds
Fund positions
56
View
Short & Settlement
Short Interest Rising
Shares short
8.9M
Days to cover
6.1d
Change
+1.8M sh
View
Short Volume
Short vol %
28%
As of
Oct 2, 2026
Short Total
View
Fails to Deliver
FTD shares
2.1K
Value
$32.2K
As of
Sep 2, 2026
View
Off-Exchange
Off-exchange %
42.1%
Week of
Aug 31, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-227.3M
EPS diluted
$-3.53
View
Filings
SEC Filings
Latest
8-K
Filed
Sep 30, 2026
This year
14
View
Proposed Sales
Value
$2.9M
Shares
150.0K
Filed
Jul 15, 2026
View
Earnings & Events
Webcasts Upcoming
Next webcast
Nov 10, 2026
Last webcast
Feb 23, 2026
View
Investor Relations
Upcoming events
7
View

Performance

5D 20D 120D MTD YTD
MLTX -5.2% -24.9% -38.1% -2.5% -13.4%
SPY -0.2% -0.5% +12.2% +0.9% +12.9%
vs SPY -5.0% -24.4% -50.3% -3.4% -26.3%
Key facts CIK 1821586 CUSIP 61559X104 13F (30d) 3 filings 3 filers Visit website Investor relations